Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -32.53% is in line with its 5-year average of -29.89%, around the middle of its 5-year range (-40.09%–-16.19%).
4.70% below its 12-month average of -31.07%.
Reported quarterly return on assets; no daily interpolation. Q3 FY2026 (2026-06-30): -6.23%.
RETURN ON ASSETS (ROA)
-32.53%
RETURN ON ASSETS (ROA) AVG TTM
-31.07%
RETURN ON ASSETS (ROA) AVG 3Y
-30.77%
RETURN ON ASSETS (ROA) AVG 5Y
-29.89%
RETURN ON ASSETS (ROA) AVG 10Y
-67.74%
RETURN ON ASSETS (ROA) AVG 15Y
-38.71%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-4.70%
CURRENT VS 3Y AVG
-5.74%
CURRENT VS 5Y AVG
-8.83%
CURRENT VS 10Y AVG
+51.98%
CURRENT VS 15Y AVG
+15.96%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.80%
median of 816 covered companies
CURRENT VS SECTOR MEDIAN
-2.30%
vs the sector median at left
Citius Pharmaceuticals, Inc.
Market Cap
$13.52M
Return on Assets (ROA)
-32.53%
TTM Avg
-31.07%
3Y Avg
-30.77%
5Y Avg
-29.89%
Market Cap
$13.51M
Return on Assets (ROA)
-27.12%
TTM Avg
-32.94%
3Y Avg
-35.27%
5Y Avg
-29.16%
Market Cap
$13.86M
Return on Assets (ROA)
-123.23%
TTM Avg
-153.35%
3Y Avg
-205.77%
5Y Avg
-166.29%
Market Cap
$13.35M
Return on Assets (ROA)
-85.85%
TTM Avg
-102.78%
3Y Avg
-95.22%
5Y Avg
-76.09%
Market Cap
$13.76M
Return on Assets (ROA)
-172.58%
TTM Avg
-148.41%
3Y Avg
-106.72%
5Y Avg
-82.10%
Market Cap
$14.04M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.11M
Return on Assets (ROA)
-15.57%
TTM Avg
-20.73%
3Y Avg
-20.84%
5Y Avg
-41.87%
Market Cap
$12.92M
Return on Assets (ROA)
-143.44%
TTM Avg
-68.17%
3Y Avg
-65.00%
5Y Avg
-57.74%
Market Cap
$12.82M
Return on Assets (ROA)
-47.98%
TTM Avg
-31.15%
3Y Avg
-42.27%
5Y Avg
-34.21%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | $13.52M | -32.53% | -31.07% | -30.77% | -29.89% |
| Optimi Health Corp. (OPTH)vs › | $13.51M | -27.12% | -32.94% | -35.27% | -29.16% |
| Vyome Holdings, Inc. (HIND)vs › | $13.86M | -123.23% | -153.35% | -205.77% | -166.29% |
| IN8bio, Inc. (INAB)vs › | $13.35M | -85.85% | -102.78% | -95.22% | -76.09% |
| Sintx Technologies, Inc. (SINT)vs › | $13.76M | -172.58% | -148.41% | -106.72% | -82.10% |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.04M | N/A | N/A | N/A | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.11M | -15.57% | -20.73% | -20.84% | -41.87% |
| Passage Bio, Inc. (PASG)vs › | $12.92M | -143.44% | -68.17% | -65.00% | -57.74% |
| Cytosorbents Corporation (CTSO)vs › | $12.82M | -47.98% | -31.15% | -42.27% | -34.21% |
| Lantern Pharma Inc. (LTRN)vs › | $12.68M | -216.84% | -118.20% | -6127.40% | -4092.56% |
ROA
-32.5%
ROE
-69.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-09-30 | -28.59% |
| 2024-09-30 | -33.55% |
| 2023-09-30 | -31.41% |
| 2022-09-30 | -29.51% |
| 2021-09-30 | -16.19% |
| 2020-09-30 | -40.09% |
| 2019-09-30 | -53.74% |
| 2018-09-30 | -40.37% |
| 2017-09-30 | -42.53% |
| 2016-09-30 | -37.79% |
| 2015-09-30 | -391.38% |
| 2014-09-30 | -81.68% |
| 2013-09-30 | -29.05% |
| 2012-09-30 | -16300.74% |
| 2011-09-30 | -12425.00% |
